Influence of Different Ratios of DSPE-PEG2k on Ester Prodrug Self-Assembly Nanoparticles for Cell Migration and Proliferation Suppression

References

• Miao L, Liu Y, Ali NM, et al. Bufalin serves as a pharmaceutic that mitigates drug resistance. Drug Metab Rev. 2023;55(3):195–204. doi:10.1080/03602532.2023.2206065
   PubMed Web of Science ®Google Scholar
• Soumoy L, Ghanem GE, Saussez S, Journe F. Bufalin for an innovative therapeutic approach against cancer. Pharmacol Res. 2022;184:106442. doi:10.1016/j.phrs.2022.106442
   PubMed Web of Science ®Google Scholar
• Yin P-H, Liu X, Qiu -Y-Y, et al. Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients. Asian Pac J Cancer Preven. 2012;13(11):5339–5343. doi:10.7314/APJCP.2012.13.11.5339
   PubMedGoogle Scholar
• Lan YL, Lou JC, Jiang X W, et al. A research update on the anticancer effects of bufalin and its derivatives. Oncol Lett. 2019;17(4):3635–3640. doi:10.3892/ol.2019.10062
   PubMed Web of Science ®Google Scholar
• Chen G, Zhang H, Sun H, et al. Bufalin targeting BFAR inhibits the occurrence and metastasis of gastric cancer through PI3K/AKT/mTOR signal pathway. Apoptosis. 2023;28(9–10):1390–1405. doi:10.1007/s10495-023-01855-z
   PubMed Web of Science ®Google Scholar
• Yuan Z, Liu C, Sun Y, et al. Bufalin exacerbates photodynamic therapy of colorectal cancer by targeting SRC-3/HIF-1α pathway. Int J Pharmaceut. 2022;624:122018. doi:10.1016/j.ijpharm.2022.122018
   PubMed Web of Science ®Google Scholar
• Ding L, Yang Y, Lu Q, et al. Bufalin inhibits tumorigenesis, stemness, and epithelial–mesenchymal transition in colorectal cancer through a C-Kit/Slug signaling axis. Int J Mol Sci. 2022;23(21):13354. doi:10.3390/ijms232113354
   PubMed Web of Science ®Google Scholar
• Chen YY, Lu HF, Hsu SC, et al. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK‐Hep1 cells through the inhibitions of NF‐kB and matrix metalloproteinase‐2/‐9‐signaling pathways. Environ Toxicol Phar. 2015;30(1):74–82. doi:10.1002/tox.21896
   Google Scholar
• Fu R, Yu F, Wu W, et al. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding. Int Immunopharmacol. 2021;101:108195. doi:10.1016/j.intimp.2021.108195
   PubMed Web of Science ®Google Scholar
• Yu Z, Li Y, Li Y, et al. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma. J Immunother Cancer. 2022;10(5):e004297. doi:10.1136/jitc-2021-004297
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang C, Chi H, Meng Z. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. Int J Oncol. 2018;52(6):2051–2060. doi:10.3892/ijo.2018.4351
   PubMed Web of Science ®Google Scholar
• Huang H, Lin X-J, Lin Y, Yao R-X, M-q H. Bufalin enhances the cytotoxity of human multiple myeloma cells H929 to AKT inhibitor MK2206: the role of protein AKT phosphorylation. Indian J Hematol Blo. 2018;34(2):268–272. doi:10.1007/s12288-017-0883-z
   PubMed Web of Science ®Google Scholar
• Liu F, Tong D, Li H, et al. Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin α2/β5/FAK signaling pathway. Oncotarget. 2016;7(8):8896–8907. doi:10.18632/oncotarget.6840
   PubMedGoogle Scholar
• Cheng CS, Wang J, Chen J, et al. New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of huachansu and its main active constituent bufalin. Can Cell Inter. 2019;19(1):92. doi:10.1186/s12935-019-0806-1
   PubMedGoogle Scholar
• Zhang W, Fan Y, Zhang J, et al. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer. Drug Resist Update. 2023;71:101005. doi:10.1016/j.drup.2023.101005
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang L, He F, et al. Surfactant assisted rapid-release liposomal strategies enhance the antitumor efficiency of bufalin derivative and reduce cardiotoxicity. Int J Nanomed. 2021;16:3581–3598. doi:10.2147/IJN.S313153
   PubMed Web of Science ®Google Scholar
• Hong X, Cai Z, Zhou F, et al. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. Front Pharmacol. 2022;13:932934. doi:10.3389/fphar.2022.932934
   PubMed Web of Science ®Google Scholar
• Mazumder K, Hossain ME, Aktar A, et al. In silico analysis and experimental evaluation of ester prodrugs of ketoprofen for oral delivery: with a view to reduce toxicity. Processes. 2021;9(12):2221. doi:10.3390/pr9122221
   Web of Science ®Google Scholar
• Jornada DH, Dos Santos Fernandes GF, Chiba DE, et al. The prodrug approach: a successful tool for improving drug solubility. Molecules. 2015;21(1):42. doi:10.3390/molecules21010042
   PubMed Web of Science ®Google Scholar
• Xiang J, Liu J, Liu X, et al. Enzymatic drug release cascade from polymeric prodrug nanoassemblies enables targeted chemotherapy. J Control Release. 2022;348:444–455. doi:10.1016/j.jconrel.2022.06.007
   PubMed Web of Science ®Google Scholar
• Liu T, Yuan X, Jia T, et al. Polymeric prodrug of bufalin for increasing solubility and stability: synthesis and anticancer study in vitro and in vivo. Int J Pharmaceut. 2016;506(1–2):382–393. doi:10.1016/j.ijpharm.2016.04.041
   PubMed Web of Science ®Google Scholar
• Li Y, Ye C, Cai C, et al. Design and synthesis of polymer prodrugs for improving water-solubility, pharmacokinetic behavior and antitumor efficacy of TXA9. Pharm Res-DORDR. 2020;37(3):1–14. doi:10.1007/s11095-020-02789-w
   Web of Science ®Google Scholar
• Dong H, Pang L, Cong H, Shen Y, Yu B. Application and design of esterase-responsive nanoparticles for cancer therapy. Drug Deliv. 2019;26(1):416–432. doi:10.1080/10717544.2019.1588424
   PubMed Web of Science ®Google Scholar
• Yang L, Xu J, Xie Z, et al. Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo. Asian J Pharm Sci. 2021;16(6):762–771. doi:10.1016/j.ajps.2021.08.001
   PubMed Web of Science ®Google Scholar
• Zhang H, Wei S, Zhang Y, et al. Improving cellular uptake and bioavailability of periplocymarin-linoleic acid prodrug by combining PEGylated liposome. Drug Deliv. 2022;29(1):2491–2497. doi:10.1080/10717544.2022.2104406
   PubMed Web of Science ®Google Scholar
• Wang X, Yang B, Li L, et al. Probing the fluorination effect on the self-assembly characteristics, in vivo fate and antitumor efficacy of paclitaxel prodrug nanoassemblies. Theranostics. 2021;11(16):7896–7910. doi:10.7150/thno.61337
   PubMed Web of Science ®Google Scholar
• Zhang H-Y, C-y S, Adu-Frimpong M, J-n Y, X-m X. Glutathione-sensitive PEGylated curcumin prodrug nanomicelles: preparation, characterization, cellular uptake and bioavailability evaluation. Int J Pharmaceut. 2019;555:270–279. doi:10.1016/j.ijpharm.2018.11.049
   PubMed Web of Science ®Google Scholar
• Wang J, Matayoshi E. Solubility at the molecular level: development of a Critical Aggregation Concentration (CAC) assay for estimating compound monomer solubility. Pharm Res-DORDR. 2012;29(7):1745–1754. doi:10.1007/s11095-012-0730-8
   PubMed Web of Science ®Google Scholar
• Meewan J, Somani S, Almowalad J, et al. Preparation of zein-based nanoparticles: nanoprecipitation versus microfluidic-assisted manufacture, effects of PEGylation on nanoparticle characteristics and cellular uptake by melanoma cells. Int J Nanomed. 2022;17:2809–2822. doi:10.2147/IJN.S366138
   PubMed Web of Science ®Google Scholar
• Wang Q, Liang Q, Dou J, et al. Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours. Nat Nanotechnol. 2023. doi:10.1038/s41565-023-01498-w
   Web of Science ®Google Scholar
• Wang H, Chen J, Xu C, et al. Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of Drug combinations. Theranostics. 2017;7(15):3638–3652. doi:10.7150/thno.20028
   PubMed Web of Science ®Google Scholar
• Li Y, Li L, Jin Q, et al. Impact of the amount of PEG on prodrug nanoassemblies for efficient cancer therapy. Asian J Pharm Sci. 2022;17(2):241–252. doi:10.1016/j.ajps.2022.02.002
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99(Pt A):28–51. doi:10.1016/j.addr.2015.09.012
   PubMed Web of Science ®Google Scholar
• Yang Y-H, Aloysius H, Inoyama D, Chen Y, L-q H. Enzyme-mediated hydrolytic activation of prodrugs. Acta Pharm Sin B. 2011;1(3):143–159. doi:10.1016/j.apsb.2011.08.001
   Google Scholar
• Tian C, Guo J, Miao Y, et al. Triglyceride-mimetic structure-gated prodrug nanoparticles for smart cancer therapy. J Med Chem. 2021;64(21):15936–15948. doi:10.1021/acs.jmedchem.1c01328
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Hayes ME, Noble CO, et al. Drug stability and minimized acid-/drug-catalyzed Phospholipid degradation in liposomal irinotecan. J Pharm Sci-US. 2023;112(2):416–434. doi:10.1016/j.xphs.2022.11.025
   PubMed Web of Science ®Google Scholar
• Huang R, Carney RP, Ikuma K, Stellacci F, Lau BL. Effects of surface compositional and structural heterogeneity on nanoparticle–protein interactions: different protein configurations. ACS nano. 2014;8(6):5402–5412. doi:10.1021/nn501203k
   PubMed Web of Science ®Google Scholar
• Liang P, Zhang Y, Schmidt BF, et al. Esterase-activated, pH-responsive, and genetically targetable nano-prodrug for cancer cell photo-ablation. Small. 2023;19(19):2207535. doi:10.1002/smll.202207535
   Web of Science ®Google Scholar
• Xia KS, Li DD, Wang CG, et al. An esterase-responsive ibuprofen nano-micelle pre-modified embryo derived nucleus pulposus progenitor cells promote the regeneration of intervertebral disc degeneration. Bioact Mater. 2023;21:69–85. doi:10.1016/j.bioactmat.2022.07.024
   PubMed Web of Science ®Google Scholar
• D-Z X, Sun X-Y, Liang Y-X, et al. Esterase-responsive polymeric micelles containing tetraphenylethene and poly(ethylene glycol) moieties for efficient doxorubicin delivery and tumor therapy. Bioconjugate Chem. 2023;34(1):248–256. doi:10.1021/acs.bioconjchem.2c00545
   PubMedGoogle Scholar
• Wang X-W, Yang Z-Y, Li T, et al. Verteporfin exerts anticancer effects and reverses resistance to paclitaxel via inducing ferroptosis in esophageal squamous cell cancer cells. Mol Biotechnol. 2023. doi:10.1007/s12033-023-00891-z
   Web of Science ®Google Scholar
• Shim N, Jeon SI, Yang S, et al. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy. Biomaterials. 2022;289:121806. doi:10.1016/j.biomaterials.2022.121806
   PubMed Web of Science ®Google Scholar
• Yan F, Zhang C, Zheng Y, et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomed-Nanotechnol. 2010;6(1):170–178. doi:10.1016/j.nano.2009.05.004
   PubMed Web of Science ®Google Scholar
• Zahednezhad F, Mojarrad JS, Zakeri-Milani P, et al. Surface modification with cholesteryl acetyl carnitine, a novel cationic agent, elevates cancer cell uptake of the PEGylated liposomes. Int J Pharmaceut. 2021;609:121148. doi:10.1016/j.ijpharm.2021.121148
   PubMed Web of Science ®Google Scholar
• Yang W, Wang L, Fang M, et al. Nanoparticle surface engineering with heparosan polysaccharide reduces serum protein adsorption and enhances cellular uptake. Nano lett. 2022;22(5):2103–2111. doi:10.1021/acs.nanolett.2c00349
   PubMed Web of Science ®Google Scholar
• Yang G, Liu Y, Hui Y, et al. Implications of quenching‐to‐dequenching switch in quantitative cell uptake and biodistribution of dye‐labeled nanoparticles. Angew Chem Int Edit. 2021;60(28):15426–15435. doi:10.1002/anie.202101730
   Web of Science ®Google Scholar
• Wang H, Zhou W, Fu J, et al. Research on the mechanism of bufalin inhibiting migration and invasion of human prostate cancer PC3 cells. Acta Pharma Sin. 2022;57(5):1361–1366.
   Google Scholar
• Guo C, Yuan H, Wang Y, et al. The interplay between PEGylated nanoparticles and blood immune system. Adv Drug Deliv Rev. 2023;200:115044. doi:10.1016/j.addr.2023.115044
   PubMed Web of Science ®Google Scholar
• Liu T, Li L, Wang S, et al. Hybrid chalcogen bonds in prodrug nanoassemblies provides dual redox-responsivity in the tumor microenvironment. Nat Commun. 2022;13(1):7228. doi:10.1038/s41467-022-35033-7
   PubMed Web of Science ®Google Scholar